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Amphipathic α-helical antimicrobial peptides comprise a class of broad-spectrum agents that are used against pathogens. We
designed a series of antimicrobial peptides, CP-P (KWKSFIKKLTSKFLHLAKKF) and its derivatives, and determined their
minimum inhibitory concentrations (MICs) against Pseudomonas aeruginosa, their minimum hemolytic concentrations (MHCs)
for human erythrocytes, and the Therapeutic Index (MHC/MIC ratio). We selected the derivative peptide K11, which had the
highest therapeutic index (320) among the tested peptides, to determine the MICs against Gram-positive and Gram-negative
bacteria and 22 clinical isolates including Acinetobacter baumannii, methicillin-resistant Staphylococcus aureus, Pseudomonas
aeruginosa, Staphylococcus epidermidis, and Klebsiella pneumonia. K11 exhibited low MICs (less than 10μg/mL) and broad-
spectrum antimicrobial activity, especially against clinically isolated drug-resistant pathogens. Therefore, these results indicate
that K11 is a promising candidate antimicrobial peptide for further studies.
1.Introduction
The extensive and intensive use of antibiotics has led to the
emergence of resistant strains of bacteria. During the last
few years, only three new types of antibiotics have been
developed for clinical use [1]. Antimicrobial peptides have
been identiﬁed from a wide variety of sources, including
bacteria, insects, plants, and animals [2, 3]. Most native
antimicrobial peptides are eﬀective against a broad spectrum
of pathogens but can also be toxic to normal cells [4].
The intensive study of the structure and function of
antimicrobial peptides has led to the development and
clinical application of many peptides with enhanced activity
andlowtoxicity;thesepeptideshavebeendevelopedthrough
sequence splicing, amino acid substitution, and changing the
ratio of hydrophobic amino acids [5–7]. Among them, α-
helical antimicrobial peptides are one of the most studied
types [8]. CP26, composed of the N-terminal 8 amino acid
residues of cecropin A1 and the N-terminal 18 amino acid
residues of melittin, has high antimicrobial activity and
low toxicity [9]. P18, composed of 8 amino acid residues
of the N-terminus of cecropin A1 and the N-terminal 12
amino acid residues of magainin 2, showed satisfactory
antimicrobial activity and no toxicity [10].
In this study, CP26 and P18 were chosen as template
peptides for the synthesis of CP-P, which is composed of
amino acids 1 to 11 at the N-terminus (KWKSFIKKLTS)
of CP26 and amino acids 10 to 18 at the C-terminus
(KFLHLAKKF)ofP18.CP-Pwasmodiﬁedtoyieldanumber
of peptides with single amino acid substitutions at diﬀerent
sites on the polar or nonpolar faces, and their therapeutic
indices (MIC/MHC) were evaluated against Pseudomonas
aeruginosa. The in vitro activities of the selected peptides
with high therapeutic indices were evaluated against a set
of multiresistant clinical isolates of both Gram-positive
and Gram-negative pathogens. The results indicate that
the modiﬁcations changed the antimicrobial activities and
hemolytic toxicities. Among the derivatives, K11 exhibited
a high therapeutic index and may have potential for use in
further studies.2 International Journal of Microbiology
2.MaterialsandMethods
2.1. Bacterial Strains. Twenty-two clinical isolates and night
standard laboratory strains were used in this study: 4 Acine-
tobacter baumannii,4Pseudomonas aeruginosa, 3 Staphylo-
coccus epidermidis,a n d6Klebsiella pneumonia (Changhai
Hospital, Shanghai, China); 5 methicillin-resistance Staphy-
lococcus aureus (Ruijin Hospital, Shanghai, China); Staphy-
lococcus aureus CMCC26003; Bacillus subtilis DB430; Bacil-
lus pumilus CMCC63202; Micrococcus luteus CMCC28001;
E. coli ATCC8099; Klebsiella pneumoniae CMCC46117;
Salmonella paratyphi B CMCC50094; Pseudomonas aerug-
inosa CMCC10104; Micrococcus S1.634. In addition, Pseu-
domonasaeruginosaCMCC10104wasusedduringthedesign
of the peptides for evaluating antimicrobial activities. All
strains were cultured on Mueller-Hinton medium.
2.2. Design of Peptides. CP-P was designed by splicing the
sequences of CP26 and P18. S16, which has a single amino
acid change at the 16th site of CP-P, served as a template
peptide from which several peptides were derived by single
amino acid substitution at diﬀerent sites. All of the peptide
sequences are listed in Table 1.
2.3. Synthesis and Puriﬁcation of Peptides. The syntheses of
the peptides CP26, P18, CP-P, S16, and the S16 derivatives (a
total of 23) were carried out by solid-phase peptide synthesis
(SPPS) [11]. The crude peptides were puriﬁed by RP-HPLC
using a Kromasil C18-5 column at a ﬂow rate of 1mL/min
with a linear AB gradient (1% acetonitrile/min); mobile
phase A was 0.1% triﬂuoroacetic in 100% water, and mobile
phase B was 0.1% triﬂuoroacetic in 100% acetonitrile. The
identities of the puriﬁed peptides were conﬁrmed by mass
spectrometry.
2.4. Circular Dichroism (CD). CD spectra were obtained
with a Jasco J-710 instrument (Jasco, Tokyo, Japan) utilizing
quartz cells with a 2mm path length and peptide concentra-
tions of 100μM in a 10mM sodium phosphate buﬀer with
a pH of 7.5 containing 50% triﬂuoroethanol. Each spectrum
was obtained from an average of 5 pairs of duplicates, and
the percentage helicity of each peptide was determined [12].
2.5. Measurement of the Antibacterial Activity. The antibac-
terial activities of the diﬀerent peptides were evaluated using
the minimum inhibitory concentration (MIC). The process
followed the standard microtiter dilution method in LB
medium without salt. Brieﬂy, bacteria were grown overnight
in LB at 37◦C and diluted in the same medium. Then,
100μL of the medium was dispensed into each well of a
96-well plate. The number of bacteria was between 104 and
105 CFU/mL. Serial dilutions of peptides were performed
consecutively in each well in 10μL. Plates were incubated at
37◦C for 24h; then, the OD620 was measured to determine
t h eM I Co fe a c hp e p t i d e[ 13].
2.6. Measurement of Hemolytic Activity (MHC). The MHCs
were measured by the method as described in Chen et
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Figure 1: Helical wheel structure and sequence of peptide CP-P.
al. [7] :p e p t i d e sw e r ea d d e dt o1 %h u m a ne r y t h r o c y t e s
in phosphate-buﬀered saline (0.08mol/L NaCl, 0.043mol/L
Na2HPO4, 0.011mol/L KH2PO4)a n dt h e nk e p ta t3 7 ◦Cf o r
1h in microtiter plates. The supernatants were collected by
centrifugation (800g), and the OD562 of each supernatant
was determined. We chose a 0.1% Triton X-100 solution as
the positive control because this solution causes the total
release of hemoglobin. We deﬁned the MHC as the highest
peptide concentration that caused no detectable release of
hemoglobin (the ratio of the OD562 for the peptide solution
to the OD562 for the positive control should be less than 1%).
3. Results
3.1. Design and Construction of Peptides. All of the peptides
were designed based on a CP-P template, which had a higher
therapeutic index than P18 and P26. S16, a derivative of
CP-P with only one amino acid substitution at the 16th
site, exhibited an 8-fold on the therapeutic index. This
result indicates that a polar amino acid substitution on
the nonpolar face could decrease the amphipathicity and
inﬂuence the antimicrobial activity to some extent. Figure 1
[14] shows the helical wheel structure of CP-P, which
illustrates the polar and non-polar faces of CP-P clearly.
We chose speciﬁc sites for single amino acid substitutions,
constructed a series of peptides and then calculated the
therapeutic index of all of the derivatives.
3.2. The Puriﬁcation and Determination of the Molecular
Conﬁrmation of the Peptides. After puriﬁcation, the designedInternational Journal of Microbiology 3
Table 1: Peptide sequences.
Peptide Sequence MW (Calc)a MW (Deter)b
CP26 KWKSFIKKLTSAAKKVVTTAKPLISS-NH2 2859.7 2860.5
P18 KWKLFKKIPKFLHLAKKF-NH2 2299.4 2300.5
CP-P KWKSFIKKLTSKFLHLAKKF-NH2 2480.1 2479.1
S16 KWKSFIKKLTSKFLHSAKKF-NH2 2453 2452.1
F2 KFKSFIKKLTSKFLHSAKKF-NH2 2415 2414.1
N3 KWNSFIKKLTSKFLHSAKKF-NH2 2439.9 2439.1
K6 KWKSFKKKLTSKFLHSAKKF-NH2 2469 2468.1
N7 KWKSFINKLTSKFLHSAKKF-NH2 2439.9 2438.9
A9 KWKSFIKKAKTSFLHSAKKF-NH2 2411.9 2410.7
K9 KWKSFIKKKTSKFLHSAKKF-NH2 2469 2468.1
S9 KWKSFIKKSTSKFLHSAKKF-NH2 2427.9 2426.7
R9 KWKSFIKKRTSKFLHSAKKF-NH2 2497 2496.1
A10 KWKSFIKKLASKFLHSAKKF-NH2 2424 2424.1
L10 KWKSFIKKLLSKFLHSAKKF-NH2 2466 2465.1
D11 KWKSFIKKLTDKFLHSAKKF-NH2 2482 2481.7
K11 KWKSFIKKLTKKFLHSAKKF-NH2 2495.1 2494.4
L11 KWKSFIKKLTLKFLHSKKKF-NH2 2480.1 2479.2
A13 KWKSFIKKLTSKALHSAKKF-NH2 2377.9 2378.1
K13 KWKSFIKKLTSKKLHSAKKF-NH2 2435 2434.3
K17 KWKSFIKKLTSKFLHSKKKF-NH2 2511.1 2510.2
D18 KWKSFIKKLTSKFLHSADKF-NH2 2440.9 2440.2
N18 KWKSFIKKLTSKFLHSANKF-NH2 2439.9 2440
N20 KWKSFIKKLTSKFLHSAKKN-NH2 2420.9 2419.6
aCalculated using BioPerl.
bDetermined using mass spectrometry.
Table 2: The MICs, MHCs, and therapeutic indices of the designed peptides.
Peptide MIC (μg/mL) MHC (μg/mL) Therapeutic index Hydrophobicity Hydrophobic moment %Helix Net charge
P18 25 250 10 0.486 0.405 N 7
CP-P 12.5 250 20 0.411 0.648 63.2 7
S16 3.125 >500 160 0.323 0.596 71.8 7
F2 12.5 250 20 0.3 0.574 N 7
N3 12.5 N N 0.343 0.599 72.5 6
K6 12.5 N N 0.184 0.471 N 8
N7 12.5 >500 40 0.343 0.586 72.1 6
K9 >50 N N 0.189 0.495 51.5 8
S9 50 >500 10 0.236 0.529 68.2 7
R9 >50 N N 0.188 0.494 N 8
A9 25 >500 20 0.254 0.496 64.6 7
L10 12.5 <125 10 0.395 0.632 72.1 7
A10 12.5 250 20 0.326 0.597 72.5 7
D11 25 >500 20 0.287 0.631 71.6 6
K11 1.6 >500 320 0.276 0.642 67.4 8
L11 >50 N N 0.411 0.513 N 7
A13 6.25 >500 80 0.249 0.522 45.9 7
K13 >50 N N 0.184 0.457 62.6 8
K17 12.5 >500 40 0.258 0.551 58.7 8
D18 25 >500 20 0.343 0.587 51.4 5
N18 6.25 >500 80 0.343 0.58 37.2 6
N20 6.25 >500 80 0.204 0.483 N 7
Note: “N” signiﬁes that the data were not determined.4 International Journal of Microbiology
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Figure 2: Analysis of the purity of peptide S16 by HPLC
Table 3: MIC tests on four strains of clinical Acinetobacter
baumannii isolates.
Peptide MIC (μg/ m L )
b-01 b-02 b-03 b-04
P18 6.25 25 12.5 12.5
S16 3.125 6.25 6.25 3.125
K11 0.8 3.125 3.25 1.6
peptides were analyzed by RP-HPLC, which showed that
their purities were greater than 90%. Figure 2 shows that
peptide S16 reached a purity of 92.3% after puriﬁcation. The
S16 peak was collected and analyzed by mass spectrometry.
Table 1 shows that the mass spectrometry results of the
synthetic peptides matched well with those calculated by
BioPerl [15].
3.3. Evaluation of the Designed Peptides. After the mutation
of the 16th site to serine (S16), the MIC decreased to 1/4
of that of CP-P (Table 2). Table 2 also provides information
about other peptides that are based on modiﬁcations of
S16 by amino acid substitutions. Among these 21 peptides,
peptide K11 showed the highest eﬃcacy, with an MIC
of 1.6μg/mL, an MHC of more than 500μg/mL and a
therapeutic index of 320.
The hydrophobic moments were determined with the
HeliQuest web server [16], which can be used to evaluate
amphipathicity. The percent helix values were determined
based on CD spectra.
3.4.AntimicrobialActivityAgainstClinicalAcinetobacterBau-
mannii Isolates. After comparison, three designed peptides,
S16, K11, and P18, were chosen to use in MIC tests on
four strains of clinically isolated Acinetobacter baumannii.
Table 3 illustrates that peptide K11 had the lowest MICs
Table 4: MICs of peptide K11 for diﬀerent bacteria.
Bacteria MIC (μg/mL)
Gram-positive bacteria
Staphylococcus aureus
CMCC26003 0.5
Bacillus subtilis
DB430 2
Bacillus pumilus
CMCC63202 0.5
Soluble wall Micrococcus
S1.634 1
Micrococcus luteus
CMCC28001 2
Gram-negative bacteria
E. coli
ATCC8099 0.5
Klebsiella pneumoniae
CMCC46117 2
Salmonella paratyphi B
CMCC50094 2
Pseudomonas aeruginosa
CMCC10104 4
Table 5: MICs of K11 for clinically isolated bacteria.
Bacteria MIC (μg/mL)
MRSA (5) 0.25−4
Pseudomonas aeruginosa (4) 1.0−8.0
Staphylococcus epidermidis (3) 0.5−8
Klebsiella pneumonia (6) 0.5−4.0
for the four strains of Acinetobacter baumannii; these MICs
werebetween0.8and3.25μg/mL.Uponconsiderationofthis
result, we evaluated the antimicrobial activity of K11 against
clinical isolates of both Gram-positive and Gram-negative
pathogens.
3.5. Antimicrobial Activity of Peptide K11 Against Diﬀerent
Bacteria. Similar to the results above, peptide K11 had a
lower MIC than the other designed peptides. Table 4 shows
theMICsofK11againstdiﬀerentbacteria,revealingthatK11
exhibited broad-spectrum antimicrobial activity.
3.6. Antimicrobial Activities of Peptide K11 Against Clinical
Isolates. The results of MIC tests on diﬀerent clinical bacte-
rial isolates can be found in Table 5. The clinically isolated
bacteria included 5 strains of MRSA, 4 strains of Pseu-
domonas aeruginosa, 3 strains of Staphylococcus epidermidis
and 6 strains of Klebsiella pneumonia. Peptide K11 exhibited
a low MIC for almost all of the strains of bacteria, which
indicated that this peptide has a high antimicrobial activity
against several clinically isolated drug-resistant bacteria.
4. Discussion
To design novel antimicrobial peptides with enhanced bio-
logical properties, we searched native antimicrobial peptidesInternational Journal of Microbiology 5
and selected CP26 and P18 as frameworks. CP26 and
P 1 8h a v eb e e nr e p o r t e dt ob et w oα-helical peptides with
high antimicrobial activities. Starting with CP26 and P18,
we designed and constructed a dozen novel peptides by
sequence splicing and amino acid substitution. Several of
these peptides had lower MICs and higher therapeutic
indices than CP26 and P18. Among them, K11 showed the
maximum antimicrobial activity and minimum eukaryotic
cell toxicity, with an MIC 1/16 of that of P18 and a 32-fold
higher therapeutic index than P18.
Recent studies on α-helical antimicrobial peptides have
revealed that the amphipathic structure plays a primary
role in the antimicrobial activity of these compounds.
The reduction of antimicrobial activity resulting from the
enhanced ability of self-aggregation caused by increasing
amphipathicity has been reported [17]. The mechanism
responsible for this eﬀect may be the reduction of the
eﬀective molecular number after self-aggregation. In our
study, we used HeliQuest to calculate the hydrophobic
moment of peptides to evaluate the amphipathicity and
came to the conclusion that high amphipathicity reduced
the therapeutic index. S16 has a lower hydrophobic moment
than CP-P (0.596 to 0.648) and was found to have a higher
therapeutic index (160 to 20). Peptides L10 and D11 have
high hydrophobic moments (0.632 and 0.631, resp.) and
exhibited low therapeutic indices (<20). The MICs increased
from 3.125μg/mL for S16 to 12.5μg/mL and 25μg/mL,
and the MHCs decreased from >500μg/mL for S16 to
<125μg/mL. These results conﬁrm the conclusion above,
but high hydrophobic moments may also lead to increased
antibacterial activities and decreased hemolytic activities.
The results agree with the results of other studies that there is
a threshold hydrophobicity at which optimal antimicrobial
activity can be achieved [18]. In this study, K11 reached
a therapeutic index of 320 and has a high hydrophobic
moment (0.642).
Wefoundthatsubstitutionsatcertainspeciﬁcsites(9,11,
and 13 from the N-terminus) can change the antimicrobial
activity of S16 more eﬀectively. The 9th residue of S16 is L,
which is on the nonpolar face. If a polar amino acid were
substituted at this site, there could be an increase in the MIC.
R9, S9, and K9 are three derivatives that showed high MICs
(>50μg/mL) and decreased hydrophobic moments (0.494,
0.529, and 0.495, resp.). The substitutions at the 11th and
13th sites with opposite polar amino acids can also lead
to signiﬁcant increases in the MIC and decreases in the
amphipathicity. We think that this structural implication
should be investigated more closely in future studies.
The net positive charge on the polar face is important for
the antimicrobial and hemolytic activities of antimicrobial
peptides [19]. We constructed K11 by changing S to K at
position 11 on the polar face of S16. This one addition to
the net charge resulted in K11 showing the best biological
properties among the tested peptides.
In conclusion, our results showed that the therapeutic
index of a peptide depends on several factors. Modiﬁcation
of speciﬁc sites can change the amphipathicity to diﬀerent
extents, which can be used to predict the antimicrobial
activity. In our study, we found a highly eﬀective peptide,
S16, and used it as template to establish a series of peptides
with single amino acid substitutions. Among these peptides,
K11 showed strong therapeutic action against antibiotic-
resistant clinical isolates of both Gram-positive and Gram-
negative bacteria, making it a promising antimicrobial
peptide candidate for further study, especially in vivo studies
and clinical tests.
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